215 related articles for article (PubMed ID: 37102330)
1. Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries.
George M; Pérez Martin J; AbdelGhany M; Gkalapi F; Jamet N; Kosse RC; Ruiz García Y; Turriani E; Berlaimont V
Hum Vaccin Immunother; 2023 Dec; 19(1):2202124. PubMed ID: 37102330
[TBL] [Abstract][Full Text] [Related]
2. Hexavalent vaccines in infants: a systematic literature review and meta-analysis of the solicited local and systemic adverse reactions of two hexavalent vaccines.
Mukherjee P; Akpo EIH; Kuznetsova A; Knuf M; Silfverdal SA; Kosalaraksa P; Mihalyi A
Expert Rev Vaccines; 2021 Mar; 20(3):319-330. PubMed ID: 33660582
[No Abstract] [Full Text] [Related]
3. Hexavalent vaccines: What can we learn from head-to-head studies?
Knuf M; Haas H; Garcia-Corbeira P; Turriani E; Mukherjee P; Janssens W; Berlaimont V
Vaccine; 2021 Oct; 39(41):6025-6036. PubMed ID: 34531081
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA
Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
Klein NP; Abu-Elyazeed R; Cheuvart B; Janssens W; Mesaros N
Hum Vaccin Immunother; 2019; 15(4):809-821. PubMed ID: 30444673
[TBL] [Abstract][Full Text] [Related]
6. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
[TBL] [Abstract][Full Text] [Related]
7. Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine.
Lim FS; Han HH; Jacquet JM; Bock HL
Ann Acad Med Singap; 2007 Oct; 36(10):801-6. PubMed ID: 17987229
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
[TBL] [Abstract][Full Text] [Related]
9. Safety profile of
Puente Gómez I; Verheust C; Hanssens L; Dolhain J
Expert Rev Vaccines; 2020 Aug; 19(8):771-779. PubMed ID: 32729745
[TBL] [Abstract][Full Text] [Related]
10. Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region.
Dolhain J; Janssens W; Sohn WY; Dindore V; Mukherjee P
Expert Rev Vaccines; 2019 Sep; 18(9):921-933. PubMed ID: 31328999
[No Abstract] [Full Text] [Related]
11. Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants.
Zepp F; Schuind A; Meyer C; Sänger R; Kaufhold A; Willems P
Pediatrics; 2002 Apr; 109(4):e58. PubMed ID: 11927731
[TBL] [Abstract][Full Text] [Related]
12. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers.
Quiambao B; Van Der Meeren O; Kolhe D; Gatchalian S
Hum Vaccin Immunother; 2012 Mar; 8(3):347-54. PubMed ID: 22330958
[TBL] [Abstract][Full Text] [Related]
13. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity.
Omeñaca F; Vázquez L; Garcia-Corbeira P; Mesaros N; Hanssens L; Dolhain J; Gómez IP; Liese J; Knuf M
Vaccine; 2018 Feb; 36(7):986-996. PubMed ID: 29336924
[TBL] [Abstract][Full Text] [Related]
14. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB).
Bar-On ES; Goldberg E; Hellmann S; Leibovici L
Cochrane Database Syst Rev; 2012 Apr; (4):CD005530. PubMed ID: 22513932
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A
Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
[TBL] [Abstract][Full Text] [Related]
17. Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine.
Bayliss J; Nissen M; Prakash D; Richmond P; Oh KB; Nolan T
Hum Vaccin Immunother; 2021 Jan; 17(1):176-190. PubMed ID: 32573398
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule.
Avdicová M; Prikazský V; Hudecková H; Schuerman L; Willems P
Eur J Pediatr; 2002 Nov; 161(11):581-7. PubMed ID: 12424582
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ
Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
Dhillon S
BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
